Typhoid Fever Vaccines Market
By Vaccine Type;
Live Attenuated Vaccine, Capsular Polysaccharide Vaccines, Conjugate Vaccine and OthersBy Route of Administration;
Oral and ParenteralBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031)Typhoid Fever Vaccines Market Overview
Typhoid Fever Vaccines Market (USD Million)
Typhoid Fever Vaccines Market was valued at USD 305.03 million in the year 2024. The size of this market is expected to increase to USD 549.06 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.8%.
Typhoid Fever Vaccines Market
*Market size in USD million
CAGR 8.8 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 8.8 % |
| Market Size (2024) | USD 305.03 Million |
| Market Size (2031) | USD 549.06 Million |
| Market Concentration | Medium |
| Report Pages | 343 |
Major Players
- GlaxoSmithKline Plc
- Sanofi SA
- Bharat Biotech
- Bio-Med Pvt. Ltd
- PT Bio Farma
- PaxVax, Inc
- Shanghai Institute of Biological Products Co., Ltd
- Prokarium
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Typhoid Fever Vaccines Market
Fragmented - Highly competitive market without dominant players
The Typhoid Fever Vaccines Market is experiencing robust expansion, driven by increasing awareness and the urgency to control typhoid infections. Over 60% of healthcare providers are incorporating typhoid vaccines as part of routine immunization programs. The demand is further amplified by heightened investments in vaccine development, emphasizing opportunities for advanced formulation strategies. Rapid technological progress in vaccine platforms is accelerating both growth and reliability of immunization efforts.
Technological Advancements and Innovation
Innovative developments in conjugate vaccine technologies have transformed the effectiveness of typhoid prevention, leading to adoption rates surpassing 55% in some public health initiatives. These technological advancements have improved long-term immunity and reduced reliance on repeated dosages. The focus on innovation is fostering newer delivery methods, which is encouraging broader use across healthcare systems and enhancing long-term market expansion.
Policy Support and Infrastructure Development
Government health authorities and NGOs are supporting infrastructure development to enhance vaccine accessibility, with policy initiatives accounting for over 65% of recent distribution improvements. These proactive steps are unlocking expansion pathways by boosting supply chain efficiency and cold-chain reliability. These regulatory efforts are aligning with industry efforts to improve delivery outcomes and build a resilient healthcare framework.
Future Outlook and Emerging Opportunities
The future outlook for the Typhoid Fever Vaccines Market is anchored in expanding immunization programs and rising public health investments. An estimated 70% of research funding is now directed at optimizing efficacy and minimizing side effects. The emphasis on opportunities such as needle-free delivery systems and global disease eradication initiatives positions this sector for sustained growth, marked by continuous technological innovation and public-private collaboration.
Typhoid Fever Vaccines Market Recent Developments
-
In April 2022, the Government of Nepal launched the Typhoid Conjugate Vaccine (TCV) campaign in partnership with Gavi, UNICEF, and the WHO, targeting 95% coverage for around 7.5 million children and identifying zero-dose children.
-
In April 2018, the WHO revised its guidelines to promote typhoid vaccination as a key strategy for disease elimination, emphasizing its importance in regions with high infection rates.
Typhoid Fever Vaccines Market Segment Analysis
In this report, the Typhoid Fever Vaccines Market has been segmented by Vaccine Type, Route of Administration, End User and Geography.
Typhoid Fever Vaccines Market, Segmentation by Vaccine Type
The Typhoid Fever Vaccines Market has been segmented by Vaccine Type into Live Attenuated Vaccine, Capsular Polysaccharide Vaccines, Conjugate Vaccine, and Others.
Live attenuated vaccine
Live attenuated vaccines account for nearly 22% of the typhoid fever vaccines market. These vaccines are known for their long-lasting immunity and are commonly used in endemic regions due to ease of administration and effectiveness.
Capsular polysaccharide vaccines
This segment holds about 28% market share. These vaccines are valued for their quick immune response and are often used in adult populations, especially during travel to high-risk areas.
Conjugate vaccine
Conjugate vaccines dominate the market with a share of approximately 40%. Their growing adoption is due to their high efficacy in young children and long-term protection, making them suitable for inclusion in immunization programs.
Others
The remaining 10% consists of experimental and combination vaccine types. These options are gaining interest for research potential and broader coverage in future vaccine developments.
Typhoid Fever Vaccines Market, Segmentation by Route of Administration
The Typhoid Fever Vaccines Market has been segmented by Route of Administration into Oral and Parental.
Oral
The oral route of administration represents nearly 35% of the typhoid fever vaccines market. Oral vaccines are preferred for their convenience and non-invasive nature, making them especially suitable for mass immunization in developing countries.
Parental
Parental administration dominates the market with around 65% share. This method ensures a more controlled dosage and stronger immune response, making it the preferred option in clinical and institutional healthcare settings.
Typhoid Fever Vaccines Market, Segmentation by End User
The Typhoid Fever Vaccines Market has been segmented by End User into Hospitals & Clinics, Specialty Centers, and Others.
Hospitals & Clinics
Hospitals and clinics account for approximately 55% of the market share due to their wide accessibility and comprehensive healthcare services. These settings play a critical role in the administration of typhoid vaccines, especially during outbreaks or routine immunization programs.
Specialty Centers
Specialty centers contribute about 30% to the market. These facilities are often chosen for their targeted expertise in infectious diseases and vaccinations, offering personalized and well-monitored immunization solutions.
Others
The "Others" category, including NGOs and mobile vaccination units, holds nearly 15% share. These channels are vital in reaching underserved populations and enhancing vaccine coverage in remote or rural areas.
Typhoid Fever Vaccines Market, Segmentation by Geography
In this report, the Global Typhoid Fever Vaccines Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Regions and Countries Analyzed in this Report
Typhoid Fever Vaccines Market Share (%), by Geographical Region
North America
North America holds around 25% of the global market share, driven by robust healthcare infrastructure and strong awareness of vaccine-preventable diseases. The U.S. and Canada lead in adopting preventive vaccination programs.
Europe
Europe contributes approximately 22% to the market, with increasing government support and travel-related vaccination demands. Countries like Germany, the UK, and France are key contributors due to well-regulated public health policies.
Asia Pacific
The Asia Pacific region dominates with a market share exceeding 35%, attributed to the high prevalence of typhoid in countries like India, China, and Southeast Asia. Government immunization drives and growing awareness fuel the regional market.
Middle East & Africa
This region accounts for nearly 10% of the market. Increasing efforts by international health agencies and improving healthcare accessibility contribute to rising vaccination rates against typhoid fever.
Latin America
Latin America captures about 8% of the market, with countries like Brazil and Mexico investing in public immunization programs. Enhanced disease surveillance and growing vaccine availability are boosting regional demand.
Typhoid Fever Vaccines Market Forces
This report provides an in depth analysis of various factors that impact the dynamics of Typhoid Fever Vaccines Market. These factors include; Market Drivers, Restraints and Opportunities.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces Drivers, Restraints, and Opportunities affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
| Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
|---|---|---|---|---|---|
| Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
| Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
| Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity
Drivers:
- Advancements in Vaccine Technology
- Growing Awareness about Preventive Healthcare
-
Traveler Immunization Requirements-Traveler immunization requirements play a significant role in driving the global typhoid fever vaccines market. With increasing globalization and travel to typhoid-endemic regions, many countries have implemented mandatory vaccination policies for travelers. These requirements are aimed at protecting not only the travelers themselves but also preventing the spread of typhoid fever to other regions. As a result, there's a growing demand for typhoid fever vaccines among tourists, business travelers, and expatriates.
Traveler immunization requirements are often enforced by government regulations and international health organizations. These regulations may vary depending on the destination country's endemicity status and public health policies. Some countries require proof of typhoid fever vaccination as a condition for entry, particularly for travelers coming from regions with a high prevalence of the disease. This creates a steady demand for vaccines and contributes to market growth.
For pharmaceutical companies and vaccine manufacturers, traveler immunization requirements present a lucrative market opportunity. They can tailor their marketing strategies and distribution channels to cater to the needs of travelers seeking typhoid fever vaccination. Partnerships with travel agencies, airlines, and healthcare providers can facilitate the promotion and accessibility of vaccines to travelers, further boosting market demand.
Challenges such as vaccine accessibility, affordability, and logistical issues related to cold chain management may arise in implementing traveler immunization requirements, especially in low-resource settings. Efforts to address these challenges through collaborations between governments, healthcare organizations, and vaccine manufacturers are essential to ensure widespread access to typhoid fever vaccines for travelers worldwide. Traveler immunization requirements serve as a driving force in shaping the global typhoid fever vaccines market, emphasizing the importance of vaccination in travel health and public health initiatives.
Restraints:
- Potential Side Effects and Safety Concerns
- Competitive Pricing Pressure
-
Vaccine Hesitancy-Vaccine hesitancy poses a significant challenge to the global typhoid fever vaccines market. This hesitancy stems from various factors, including concerns about vaccine safety and potential side effects. Despite the proven efficacy of typhoid fever vaccines, some individuals remain wary of immunization due to fears of adverse reactions. Addressing these concerns through transparent communication about vaccine safety data and rigorous monitoring of adverse events is crucial for overcoming hesitancy and fostering trust in vaccination programs.
Cultural beliefs and misinformation also contribute to vaccine hesitancy, particularly in communities where distrust of healthcare systems or skepticism towards Western medicine prevails. Addressing these cultural barriers requires tailored communication strategies that respect cultural sensitivities and engage with community leaders and influencers. Educating communities about the benefits of vaccination and debunking common myths and misconceptions can help alleviate concerns and increase vaccine acceptance.
The proliferation of misinformation on social media platforms has fueled vaccine hesitancy, making it imperative for public health authorities to actively combat misinformation with accurate and evidence-based information. Leveraging social media and digital platforms to disseminate factual information about typhoid fever vaccines and counter misinformation can help sway public opinion and build confidence in vaccination efforts.
Efforts to address vaccine hesitancy should also focus on improving access to vaccines, particularly in underserved communities where barriers such as affordability, lack of healthcare infrastructure, and logistical challenges hinder vaccine uptake. Implementing targeted outreach programs, mobile vaccination clinics, and community-based education initiatives can help bridge these gaps and ensure equitable access to typhoid fever vaccines, ultimately contributing to the control and prevention of this infectious disease on a global scale.
Opportunities:
- Public-Private Partnerships
- Technological Innovations
-
Medical Tourism and Travel Health Services-Medical tourism and travel health services play a crucial role in the global typhoid fever vaccines market. With the increasing ease of travel and globalization, more individuals are venturing to regions where typhoid fever is prevalent. This trend has created a growing demand for typhoid fever vaccination services among travelers, expatriates, and international students. Medical tourism hubs and travel health clinics cater to this demand by offering comprehensive vaccination packages, including typhoid fever vaccines, alongside other preventive measures to ensure the health and safety of travelers.
These specialized clinics and healthcare providers not only administer vaccines but also provide valuable information and guidance on travel-related health risks, including typhoid fever. They educate travelers about the importance of vaccination and advise on other preventive measures, such as safe food and water practices, to reduce the risk of contracting typhoid fever and other infectious diseases while abroad. By offering tailored services to meet the specific needs of travelers, medical tourism and travel health services contribute significantly to global efforts to control and prevent the spread of typhoid fever.
The rise in medical tourism has led to the establishment of dedicated travel health clinics in key tourist destinations and major cities worldwide. These clinics cater not only to inbound travelers but also to outbound travelers seeking vaccination services before embarking on their journeys. By strategically locating clinics in areas with high tourist traffic, healthcare providers can efficiently reach a diverse range of travelers and promote the importance of typhoid fever vaccination as part of their travel health preparations.
Medical tourism and travel health services present an opportunity for collaboration between healthcare providers, vaccine manufacturers, and tourism industries. By partnering with travel agencies, hotels, and airlines, healthcare providers can enhance access to vaccination services and promote proactive health management among travelers. This collaborative approach fosters a holistic approach to travel health and safety, ultimately contributing to the growth of the global typhoid fever vaccines market while ensuring the well-being of travelers worldwide.
Typhoid Fever Vaccines Market Competitive Landscape Analysis
Typhoid Fever Vaccines Market is witnessing strong competition, with pharmaceutical companies adopting strategies such as collaboration, merger, and partnerships to expand vaccine availability. More than 55% of demand is tied to public immunization programs. Continuous innovation in vaccine formulations and delivery methods supports sustainable growth across global healthcare systems.
Market Structure and Concentration
The market shows moderate concentration, with nearly 60% of share held by leading vaccine manufacturers. These firms emphasize technological advancements in conjugate vaccines and thermostable formulations. Smaller participants sustain competitiveness through regional innovation and localized strategies, while extensive collaboration with governments and NGOs drives consistent growth.
Brand and Channel Strategies
Strong brand identity and evolving channel strategies play an essential role, with more than 50% of supply linked to public health agencies and hospital networks. Vendors strengthen partnerships with distributors to extend vaccine reach. Effective collaboration and targeted strategies support trust and drive steady growth in immunization coverage.
Innovation Drivers and Technological Advancements
Over 65% of advancements are influenced by innovation in conjugate vaccines, needle-free delivery, and long-term protection methods. Manufacturers invest in technological advancements that improve efficacy and storage. Strategic collaboration with research organizations and health bodies drives novel strategies, ensuring sustained growth in typhoid fever prevention.
Regional Momentum and Expansion
Regional expansion is significant, with Asia-Pacific and Africa contributing nearly 50% of demand due to higher disease prevalence. North America and Europe emphasize innovation in vaccine distribution and compliance, while cross-border partnerships improve supply chains. Strong collaboration across regions reinforces accessibility, supporting consistent growth.
Future Outlook
The future outlook signals steady growth, with more than 70% of stakeholders expected to adopt immunization-focused strategies. Expanding collaboration and partnerships with governments, NGOs, and healthcare systems will accelerate coverage. Continuous innovation and technological advancements will play a key role in enhancing vaccine adoption and strengthening market competitiveness.
Key players in Typhoid Fever Vaccines Market include:
- GlaxoSmithKline PLC
- Sanofi S.A.
- Bharat Biotech International Limited
- PaxVax Corporation
- Bio Farma
- Prokarium
- Emergent BioSolutions
- Bio-Med Pvt. Ltd.
- Indian Immunologicals Limited
- Panacea Biotec
- SK Biosciences
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Johnson & Johnson Private Limited
In this report, the profile of each market player provides following information:
- Market Share Analysis
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Vaccine Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Region
- Typhoid Fever Vaccines Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Advancements in Vaccine Technology
- Growing Awareness about Preventive Healthcare
- Traveler Immunization Requirements
- Restraints
- Potential Side Effects and Safety Concerns
- Competitive Pricing Pressure
- Vaccine Hesitancy
- Opportunities
- Public-Private Partnerships
- Technological Innovations
- Medical Tourism and Travel Health Services
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Typhoid Fever Vaccines Market, By Vaccine Type, 2021 - 2031 (USD Million)
- Live Attenuated Vaccine
- Capsular Polysaccharide Vaccines
- Conjugate Vaccine
- Others
- Typhoid Fever Vaccines Market, By Route of Administration, 2021 - 2031 (USD Million)
- Oral
- Parenteral
- Typhoid Fever Vaccines Market, By Geography, 2021- 2031(USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Typhoid Fever Vaccines Market, By Vaccine Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- GlaxoSmithKline PLC
- Sanofi S.A.
- Bharat Biotech International Limited
- PaxVax Corporation
- Bio Farma
- Prokarium
- Emergent BioSolutions
- Bio-Med Pvt. Ltd.
- Indian Immunologicals Limited
- Panacea Biotec
- SK Biosciences
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Johnson & Johnson Private Limited
- Company Profiles
- Analyst Views
- Future Outlook of the Market

